Galectin Therapeutics Inc. (GALT)
Automate Your Wheel Strategy on GALT
With Tiblio's Option Bot, you can configure your own wheel strategy including GALT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol GALT
- Rev/Share 0.0
- Book/Share -1.9516
- PB -1.5372
- Debt/Equity -0.9761
- CurrentRatio 0.0933
- ROIC 22.9874
- MktCap 193418376.0
- FreeCF/Share -0.477
- PFCF -6.3159
- PE -5.1635
- Debt/Assets 9.5073
- DivYield 0
- ROE 0.3259
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | GALT | H.C. Wainwright | -- | Buy | -- | $6 | June 17, 2025 |
News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeutics Inc. - GALT
Published: January 22, 2026 by: PRNewsWire
Sentiment: Neutral
NEW YORK, Jan. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Galectin Therapeutics Inc. ("Galectin" or the "Company") (NASDAQ: GALT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Securities Investigation: Levi & Korsinsky Investigates Galectin Therapeutics Inc. (GALT) on Behalf of Investors
Published: January 14, 2026 by: Newsfile Corp
Sentiment: Neutral
New York, New York--(Newsfile Corp. - January 14, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Galectin Therapeutics Inc. ("Galectin Therapeutics Inc.") (NASDAQ: GALT) concerning potential violations of the federal securities laws. Galectin issued a press release on December 19, 2025, "announc[ing] that the U.S. Food and Drug Administration (FDA) has provided a written response, and subsequent communications, to the Company's previously submitted Type C meeting request regarding the development program for belapectin, its investigational galectin-3 inhibitor.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeutics Inc. - GALT
Published: January 08, 2026 by: PRNewsWire
Sentiment: Neutral
NEW YORK, Jan. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Galectin Therapeutics Inc. ("Galectin" or the "Company") (NASDAQ: GALT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
GALT Investors Have Opportunity to Join Galectin Therapeutics Inc. Fraud Investigation with the Schall Law Firm
Published: January 07, 2026 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Jan. 07, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Galectin Therapeutics Inc. (“Galectin” or “the Company”) (NASDAQ: GALT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeutics Inc. - GALT
Published: January 06, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Galectin Therapeutics Inc. (“Galectin” or the “Company”) (NASDAQ: GALT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of - GALT
Published: January 01, 2026 by: PRNewsWire
Sentiment: Neutral
NEW YORK, Jan. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Galectin Therapeutics Inc. ("Galectin" or the "Company") (NASDAQ: GALT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Galectin Therapeutics Inc. (GALT) Is Up 7.48% in One Week: What You Should Know
Published: September 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Does Galectin Therapeutics Inc. (GALT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Read More
Galectin Therapeutics Presented NAVIGATE Trial Results at the European Association for the Study of the Liver (EASL) 2025 Congress
Published: May 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
NORCROSS, Ga., May 12, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with MASH cirrhosis and portal hypertension, presented a late-breaking oral presentation of the NAVIGATE study analysis at the EASL 2025 Congress, on May 10, 2025, in Amsterdam, Netherlands. The NAVIGATE study evaluated belapectin, a galectin-3 inhibitor, in patients with MASH cirrhosis and portal hypertension.
Read More
About Galectin Therapeutics Inc. (GALT)
- IPO Date 2002-09-04
- Website https://galectintherapeutics.com
- Industry Biotechnology
- CEO Jack W. Callicutt
- Employees 15